ResMed executives filed reports on stock transactions
Michael J. Farrell, chair and CEO of ResMed, filed a notice of a proposed sale of 4,993 shares on November 9, 2026. On November 11, several company executives and directors conducted stock transactions to cover tax obligations. These reports reflect standard corporate compensation management procedures.
Key points
- ResMed CEO Michael J. Farrell filed a notice of a proposed sale of 4,993 shares on November 9, 2026, under a plan adopted on October 31, 2024.
- On November 13, 2026, insiders filed reports on transactions made on November 11 related to paying option exercise prices or tax obligations by delivering shares.
- Public reports do not state why several insiders transferred shares on November 11.
CEO transactions.
ResMed CEO Michael J. Farrell filed a notice of a proposed sale of 4,993 shares on November 9, 2026, under a plan adopted on October 31, 2024. On the same day, he exercised options for 4,993 shares and sold them on the open market, insider trading reports show.
Management reports for November 11.
On November 13, 2026, insiders filed reports on transactions made on November 11 related to paying option exercise prices or tax obligations by delivering shares. Reporting individuals included CEO Michael J. Farrell, CFO Aaron Bloomer, and global general counsel Michael J. Rider. In these transactions, Michael J. Farrell disposed of 8,111.385 shares.
Board members Harjit Gill, Jan De Witte, and Peter C. Farrell also filed separate transaction reports for November 11. Each disposed of shares to cover tax obligations or option exercise costs under corporate compensation programs.
Risks and data limitations.
Public reports do not state why several insiders transferred shares on November 11. While this is standard practice, frequent or large share disposals by insiders can sometimes be misinterpreted by market participants as a signal regarding management's internal expectations.
What to watch.
Shareholders should monitor the SEC database to track future insider transaction reports. These filings provide data on management activity and possible changes in individual company stock ownership plans.
Original sources
- 144 filing, November 9, 2026
- 4 filing, November 12, 2026
- 4 filing, November 13, 2026
- 4 filing, November 13, 2026
- 4 filing, November 13, 2026
- 4 filing, November 13, 2026
- 4 filing, November 13, 2026
- 4 filing, November 13, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Resmed
A notification in your browser or on your phone when we publish about Resmed. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
